CatalystAlertBeta

Loading market movers...

All Therapeutic Areas

🧬

Rare & Genetic Diseases

52 drugs in pipeline from 10 companies

52

Drugs in Pipeline

10

Companies

3

Upcoming Catalysts

52

Phase 3 Trials

Upcoming Catalysts

2d

days

ZLABPDUFA$1.6B

Phase 3?Unknown

FDA PDUFA Date Elzovantinib (priority)

Investigator's Choice of Therapy• Small-cell Lung Cancer

Jul 31Confirmed

Jul '26

MRKPhase 3$281.2B

✗Negative

Pembrolizumab Phase 3 Est. Readout

pembrolizumab• Non-small Cell Lung Cancer1,397

Jul 2026~Confirmed

Aug '26

BBOTPhase 2$606M

BBT-207 Phase 2 Est. Readout

BBT-207• EGFR Mutant Advanced Non-Small Cell Lung Cancer24

Aug 2026~Confirmed

00%

View all catalysts

Pipeline by Phase

Phase 3

52

Active Companies

Gilead Sciences, Inc.

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd./ADR

ASTRAZENECA PLC

BRISTOL MYERS SQUIBB CO

MERCK

NOVARTIS AG

Sanofi

AstraZeneca PLC

TAKEDA PHARMACEUTICAL CO LTD

ABBOTT LABORATORIES

Related Conditions

rare diseaseorphangeneticgene therapyhereditarymuscular dystrophycystic fibrosissickle cellhemophiliathalassemiagaucherfabrypompehunter syndromephenylketonuriapkusmaspinal muscular atrophy